Veru

Veru Inc. is a late clinical stage biopharmaceutical company headquartered in Miami, Florida, dedicated to developing and commercializing treatments for cardiometabolic and inflammatory diseases, metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome. The company is focused on the development of enobosarm, a novel oral... selective androgen receptor modulator to address muscle loss in patients undergoing weight loss therapy with glucagon-like peptide drugs, as well as for the treatment of metastatic breast cancer. Veru is also developing sabizabulin, a novel oral broad anti-inflammatory agent and microtubule disruptor for the treatment of atherosclerotic coronary artery disease and hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company operates through two segments, Commercial and Research and Development. Veru's development portfolio includes medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals. The company also markets sexual health products through its Urev division, including a female condom for dual protection against unplanned pregnancy and sexually transmitted infections, products for premature ejaculation, and treatments for benign prostatic hyperplasia, distributed through a direct-to-patient telemedicine portal that connects users with prescribers and enables patients to request prescriptions online or by mail.Read More